慢性阻塞性肺疾病合并呼吸衰竭的临床治疗分析

Clinical Treatment of Chronic Obstructive Pulmonary Disease Complicated with Respiratory Failure

目的：分析慢性阻塞性肺疾病合并呼吸衰竭的临床治疗效果。方法：收集2009～2013年我院收治的慢性阻塞性肺疾病合并呼吸衰竭患者30例作为对照组，采用常规治疗方式，收集2015年1月～2016年4月进入我院的慢性阻塞性肺疾病合并呼吸衰竭患者30例，给予其他综合治疗外，采用无创正压通气治疗，比较两组临床治疗效果。结果：实验组插管率10%，死亡率6．67%，住院时间（12.78±5.01）d明显低于对照组插管率20.0%，死亡率16.67%，住院时间（22.33±6.98）d，实验组与对照组治疗前血气分析指标差异不显著，治疗后实验组pH值、PaO2、PaCO2（7.38±0.04）、（9.23±1.78）、（6.41±1.11）明显高于对照组pH值、PaO2、PaCO2（7.31±0.05）、（9.13±1.12）、（6.52±1.09），差异显著具有统计学意义（P＜0.05）。结论：在对COPD合并呼吸衰竭患者采取对症治疗的同时，采取无创正压通气治疗方式，能够减少插管、降低死亡发生率和减少住院时间，具有良好的临床应用价值。

Objective: To analyze the clinical therapeutic effect of chronic obstructive pulmonary disease complicated with respiratory failure.Methods:Collect and analyze the treated in our hospital from 2009 to 2013 and chronic obstructive pulmonary disease with respiratory failure patients 30 cases as control group,the conventional treatment,collect and analyze January 2015 to 2016 April in 30 chronic obstructive pulmonary disease combined with respiratory failure patients in our hospital were,given comprehensive treatment,using noninvasive positive pressure ventilation in the treatment,compared two groups of clinical curative effect.Results:Experimental group intubation rate of 10%,6.67%mortality,hospitalization time(12.78±5.01)d was significantly lower than that of the control group intubation rate was 20.0%,16.67% of mortality,hospitalization time(22.33±6.98)d,the exper imental group and the control group before treatment,the blood gas analysis indexes had no significant differences,after treatment,the experimental group pH,PaO2,PaCO2(7.38±0.04),(9.23±1.78), (6.41±1.11)was significantly higher than that of control group,pH value,PaO2,PaCO2(7.31±0.05),(9.13±1.12),(6.52±1.09),difference has statistical significance(P<0.05).Conclusion:On COPD combined with respiratory failure patients symptomatic treatment also take noninvasive positive pressure ventilation treatment,can reduce intubation,reduce death rate and reduce hospitalization time,has good clinical application value.